|3Jun 20, 7:42 PM ET

Frazier Life Sciences VIII, L.P. 3

3 · Aptinyx Inc. · Filed Jun 20, 2018

Insider Transaction Report

Form 3
Period: 2018-06-20
Holdings
  • Series A-1 Convertible Preferred Stock

    Common Stock (1,047,450 underlying)
  • Series A-2 Convertible Preferred Stock

    Common Stock (1,197,076 underlying)
  • Series B Convertible Preferred Stock

    Common Stock (795,553 underlying)
Footnotes (2)
  • [F1]All series of convertible preferred stock will automatically convert into the number of shares of the Issuer's common stock on a 27.58621-for-1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
  • [F2]This report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"), FHM Life Sciences VIII, L.P. (FHM-VIII L.P."), FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC") and Patrick J. Heron. Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM VIII L.P. and owns no shares directly. Mr. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.

Documents

1 file
  • 3
    a3.xmlPrimary

    3